About CancerIQ
CancerIQ is a company based in Chicago (United States) founded in 2013. It operates as a SaaS (Software-as-a-Service) and HealthTech. CancerIQ has raised $23.87 million across 6 funding rounds from investors including Amgen, McKesson and Decathlon Capital Partners. The company has 78 employees as of December 31, 2022. CancerIQ offers products and services including CancerIQ Platform and Telehealth Genetic Counseling. CancerIQ operates in a competitive market with competitors including Tempus, Personalis, Perthera, LinkDoc and Trapelo, among others.
- Headquarter Chicago, United States
- Employees 78 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Canceriq, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$23.87 M (USD)
in 6 rounds
-
Latest Funding Round
Not available
-
Investors
Amgen
& 8 more
-
Employee Count
78
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CancerIQ
CancerIQ offers a comprehensive portfolio of products and services, including CancerIQ Platform and Telehealth Genetic Counseling.
Software for cancer risk assessment and management.
Connects patients to genetic counseling via telehealth.
People of CancerIQ
Unlock access to complete
Funding Insights of CancerIQ
CancerIQ has successfully raised a total of $23.87M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CancerIQ
CancerIQ has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, McKesson and Decathlon Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private debt funds focused on direct lending, and revenue-based financing
|
Locked | Locked | Locked | |
|
Corporate-backed venture capital is focused on the life science sector.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for CancerIQ
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CancerIQ
Investment portfolio details for CancerIQ
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CancerIQ
Detailed financials for CancerIQ
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Canceriq Comparisons
Peer comparison for CancerIQ
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CancerIQ
CancerIQ operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tempus, Personalis, Perthera, LinkDoc and Trapelo, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-based precision medicine solutions for oncology are provided.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| Locked | Locked | Locked |
Molecular cancer profiling is conducted via genomics and proteomics.
|
|
| Locked | Locked | Locked |
Oncology-focused database is provided for cancer analytics.
|
|
| Locked | Locked | Locked |
Precision medicine platform is provided for oncologists' decision support.
|
Detailed competitors of CancerIQ
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Canceriq
Complete news archive for CancerIQ
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CancerIQ
CancerIQ was founded in 2013.
CancerIQ is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Feyi Olopade is the current CEO of CancerIQ.
CancerIQ is a funded company, having raised a total of $23.87M across 6 funding rounds to date.
As of Dec 31, 2022, the latest employee count at CancerIQ is 78.
CancerIQ is engaged in providing software solutions for health systems to enhance access to genomics and oncology innovations. The company operates in the healthcare sector, specifically targeting oncology, genetics, and breast health programs. Its integrated intelligence solution is designed to improve clinical and financial outcomes by addressing workforce challenges and ensuring adherence to medical management recommendations. Tools for risk assessment, patient navigation, and care plan management are offered, alongside connections to telehealth genetic counseling networks. The platform supports providers with clinical decision tools and evidence-based guidelines while enabling seamless integration with electronic health records (EHRs).
CancerIQ's top competitors include Tempus, Personalis and Perthera.
CancerIQ offers CancerIQ Platform and Telehealth Genetic Counseling.
CancerIQ has 9 investors. Key investors include Amgen, McKesson, Decathlon Capital Partners, Merck Global Health Innovation Fund, and OSF Ventures.